Correlation Between Taichung Commercial and Medigen Biotechnology

Can any of the company-specific risk be diversified away by investing in both Taichung Commercial and Medigen Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Taichung Commercial and Medigen Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Taichung Commercial Bank and Medigen Biotechnology, you can compare the effects of market volatilities on Taichung Commercial and Medigen Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Taichung Commercial with a short position of Medigen Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Taichung Commercial and Medigen Biotechnology.

Diversification Opportunities for Taichung Commercial and Medigen Biotechnology

-0.56

Correlation Coefficient

Taichung Commercial  Medigen Biotechnology

Excellent diversification

The 3 months correlation between Taichung and Medigen is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding Taichung Commercial Bank and Medigen Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medigen Biotechnology and Taichung Commercial is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Taichung Commercial Bank are associated (or correlated) with Medigen Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medigen Biotechnology has no effect on the direction of Taichung Commercial i.e., Taichung Commercial and Medigen Biotechnology go up and down completely randomly.

Pair Corralation between Taichung Commercial and Medigen Biotechnology

Assuming the 90 days trading horizon Taichung Commercial Bank is expected to generate 0.62 times more return on investment than Medigen Biotechnology. However, Taichung Commercial Bank is 1.6 times less risky than Medigen Biotechnology. It trades about 0.02 of its potential returns per unit of risk. Medigen Biotechnology is currently generating about -0.17 per unit of risk. If you would invest  1,840  in Taichung Commercial Bank on September 29, 2024 and sell it today you would earn a total of  20.00  from holding Taichung Commercial Bank or generate 1.09% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Taichung Commercial Bank  vs.  Medigen Biotechnology

Taichung Commercial Bank

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Taichung Commercial Bank are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, Taichung Commercial is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Medigen Biotechnology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Taichung Commercial and Medigen Biotechnology

The main advantage of trading using opposite Taichung Commercial and Medigen Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Taichung Commercial position performs unexpectedly, Medigen Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Biotechnology will offset losses from the drop in Medigen Biotechnology's long position.

The idea behind Taichung Commercial Bank and Medigen Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.